Indacaterol

The First Once-daily Long-acting Beta2 Agonist for COPD

Nonfiction, Health & Well Being, Medical, Specialties, Pulmonary & Thoracic, Medical Science, Pharmacology
Cover of the book Indacaterol by , Springer Basel
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783034807098
Publisher: Springer Basel Publication: November 19, 2013
Imprint: Springer Language: English
Author:
ISBN: 9783034807098
Publisher: Springer Basel
Publication: November 19, 2013
Imprint: Springer
Language: English

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

More books from Springer Basel

Cover of the book Recent Trends in Dynamical Systems by
Cover of the book Berichte zur Resistenzmonitoringstudie 2008 by
Cover of the book Developments of Harmonic Maps, Wave Maps and Yang-Mills Fields into Biharmonic Maps, Biwave Maps and Bi-Yang-Mills Fields by
Cover of the book Tamoxifen by
Cover of the book T Lymphocytes as Tools in Diagnostics and Immunotoxicology by
Cover of the book Capsaicin as a Therapeutic Molecule by
Cover of the book Dynamische Systeme by
Cover of the book Viral Infections of the Human Nervous System by
Cover of the book Novel Natural Products: Therapeutic Effects in Pain, Arthritis and Gastro-intestinal Diseases by
Cover of the book Fluid-Structure Interaction and Biomedical Applications by
Cover of the book Inflammation and Cancer by
Cover of the book Treatment of Cystic Fibrosis and Other Rare Lung Diseases by
Cover of the book Microlocal Methods in Mathematical Physics and Global Analysis by
Cover of the book Drugs Targeting B-Cells in Autoimmune Diseases by
Cover of the book Einführung in die angewandte Geometrie by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy